ARTICLE | Company News
Triphase, Celgene deal
December 30, 2016 1:43 AM UTC
Triphase granted Celgene an option to acquire all assets relating to lymphoma candidate TRPH-222 (CD22-4AP). If Celgene exercises its option, it will be responsible for development and commercializati...